Hospital
American Hospital Management Corporation
American Hospital Management Corporation was paid $14.31M by Medicaid between Jan 2018 and Oct 2024, across 156 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 15% of everything it billed.
33Billing provider infoAMERICAN HOSPITAL MANAGEMENT CORPORATION
ARCATA, CA 95521
ARCATA, CA 95521
33aNPI1518996040assigned 06/30/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.31M
24GClaims326,820
24DCodes billed156
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#156 of 410
Median peer was paid$6.90M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 56,937 | $2.30M | |
| 2019 | 52,474 | $1.93M | |
| 2020 | 43,143 | $1.73M | |
| 2021 | 48,686 | $2.17M | |
| 2022 | 49,189 | $2.20M | |
| 2023 | 46,032 | $2.18M | |
| 2024incomplete | 30,359 | $1.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 15% | 18,877 | 17,419 | $2.11M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 33,773 | 29,767 | $2.06M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 6.9% | 7,611 | 5,314 | $984K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.8% | 33,814 | 6,512 | $687K |
| 99201 | 4.7% | 7,126 | 4,647 | $670K | |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 2,079 | 2,044 | $499K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.8% | 3,764 | 3,587 | $407K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 911 | 904 | $379K |
| 97139 | 2.0% | 14,395 | 2,893 | $293K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.9% | 1,607 | 1,597 | $266K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.8% | 2,914 | 2,857 | $256K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.8% | 1,268 | 1,265 | $251K |
144 more codes
| 97750 | 1.7% | 5,886 | $244K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 2,145 | $240K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 4,905 | $236K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 2,725 | $230K |
| 93976 | 1.5% | 538 | $211K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.4% | 1,652 | $197K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 853 | $194K |
| 86328 | 1.2% | 3,772 | $171K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.2% | 1,355 | $169K |
| 80053 | Comprehensive metabolic panel | 1.1% | 15,551 | $162K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 1,122 | $153K |
| J3490 | Unclassified drugs | 1.1% | 7,070 | $153K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 2,399 | $152K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,681 | $132K |
| 76641 | <1% | 861 | $122K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,375 | $115K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 207 | $104K |
| 80306 | <1% | 5,790 | $95K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,463 | $95K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 242 | $91K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,244 | $91K |
| 76830 | Ultrasound, transvaginal | <1% | 559 | $77K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 195 | $76K |
| 59025 | Fetal non-stress test | <1% | 2,038 | $75K |
| 73630 | <1% | 1,739 | $73K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,820 | $64K |
| 73610 | <1% | 1,325 | $64K | |
| 72100 | <1% | 1,081 | $58K | |
| 73562 | <1% | 1,399 | $57K | |
| 76801 | <1% | 567 | $57K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,037 | $55K |
| 73130 | <1% | 1,190 | $55K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,341 | $53K |
| 73110 | <1% | 1,104 | $51K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 504 | $45K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 133 | $45K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 339 | $45K |
| 73030 | <1% | 941 | $44K | |
| 90715 | <1% | 834 | $43K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 306 | $43K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,085 | $41K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 353 | $37K |
| 83880 | <1% | 1,021 | $35K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,004 | $33K |
| 82553 | <1% | 2,621 | $30K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 970 | $30K |
| 83690 | <1% | 4,397 | $29K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 664 | $29K |
| 84484 | <1% | 2,878 | $28K | |
| 83605 | <1% | 2,165 | $26K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,043 | $25K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 537 | $25K |
| 80061 | Lipid panel | <1% | 1,757 | $24K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,992 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,774 | $22K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,609 | $21K |
| 74022 | <1% | 339 | $21K | |
| 82550 | <1% | 2,909 | $19K | |
| 97799 | <1% | 888 | $19K | |
| 81015 | <1% | 5,617 | $19K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 910 | $19K |
| 87186 | <1% | 1,809 | $19K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,774 | $19K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,221 | $19K |
| 87040 | <1% | 963 | $15K | |
| 85730 | <1% | 2,544 | $15K | |
| 85610 | <1% | 3,577 | $14K | |
| 76536 | <1% | 143 | $14K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,643 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,263 | $12K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,905 | $12K |
| 84439 | <1% | 1,213 | $12K | |
| 86140 | <1% | 2,175 | $11K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 215 | $11K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,768 | $11K |
| 72040 | <1% | 239 | $11K | |
| 81003 | <1% | 4,028 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 109 | $10K |
| 73080 | <1% | 210 | $10K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 246 | $9K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,160 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 156 | $8K |
| 81001 | <1% | 1,833 | $8K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 140 | $8K |
| 97010 | <1% | 355 | $8K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 90 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,267 | $8K |
| 94664 | <1% | 334 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 196 | $7K |
| 76770 | <1% | 63 | $7K | |
| 71250 | <1% | 25 | $7K | |
| 73221 | <1% | 13 | $7K | |
| 85378 | <1% | 843 | $7K | |
| 87077 | <1% | 620 | $6K | |
| 87081 | <1% | 1,243 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 767 | $6K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $6K |
| G0202 | Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | <1% | 32 | $6K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 139 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 428 | $5K |
| A6209 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 91 | $5K |
| 76496 | <1% | 16 | $5K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 203 | $4K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 243 | $4K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 31 | $3K |
| 85007 | <1% | 759 | $3K | |
| 86850 | <1% | 976 | $3K | |
| 83540 | <1% | 477 | $3K | |
| 87075 | <1% | 258 | $3K | |
| 82962 | <1% | 851 | $3K | |
| 73502 | <1% | 57 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 170 | $3K |
| 73140 | <1% | 85 | $2K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 13 | $2K |
| 99070 | <1% | 92 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 230 | $2K |
| 85651 | <1% | 511 | $2K | |
| 82728 | <1% | 125 | $2K | |
| 86901 | <1% | 512 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 157 | $1K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 127 | $901.86 |
| 82570 | <1% | 135 | $756.71 | |
| 82746 | <1% | 45 | $715.65 | |
| 86703 | <1% | 39 | $698.31 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,136 | $658.47 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 39 | $604.01 |
| 76000 | <1% | 12 | $541.32 | |
| 86900 | <1% | 164 | $501.19 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $452.84 |
| 84156 | <1% | 136 | $445.16 | |
| 83735 | <1% | 66 | $385.77 | |
| 12001 | <1% | 12 | $340.80 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 69 | $328.41 |
| 86592 | <1% | 24 | $218.16 | |
| 82607 | <1% | 12 | $183.94 | |
| 84703 | <1% | 30 | $180.88 | |
| 82803 | <1% | 12 | $165.90 | |
| 29125 | <1% | 14 | $165.62 | |
| 84481 | <1% | 13 | $155.09 | |
| 86803 | <1% | 12 | $153.80 | |
| 88313 | <1% | 13 | $138.78 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 14 | $135.49 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 92 | $5.52 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 13 | $4.59 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHAW, DOUGLAS (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| North Pacific Cardiology Medical | Arcata, CA | $1.48M |
| American Hospital Management Corporation | Arcata, CA | $632K |
| Willow Creek - Six Rivers Medical Center | Willow Creek, CA | $237K |
| American Hospital Management Corporation | Arcata, CA | $129K |
| Humboldt Family Medical Care | Mckinleyville, CA | $59K |
| American Hospital Management | Arcata, CA | $41K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.